Abstract
Thirty percent of cases of schizophrenia have their onset before the age of 18 years. Earlier age of onset of the illness often confers increased risk for severe phenotypes and poor prognostic factors. Treatment-resistant schizophrenia (TRS) is a failure of 2 adequate trials of antipsychotic treatment. Treatment guidelines in Canada recommend the use of clozapine for TRS in youth. Rigorous and preventative monitoring strategies in Canada for the adverse events of clozapine have reduced the risk of agranulocytosis, neutropenia, myocarditis, and cardiomyopathy; however, prescribing practice in Canada remains low.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
